HC Wainwright Has Optimistic Outlook of TYRA FY2025 Earnings

Tyra Biosciences, Inc. (NASDAQ:TYRA) – Analysts at HC Wainwright raised their FY2025 earnings per share (EPS) estimates for shares of Tyra Biosciences in a research report issued on Monday, May 19th. HC Wainwright analyst M. Kapoor now forecasts that the company will earn ($2.27) per share for the year, up from their prior estimate of ($2.37). HC Wainwright has a “Buy” rating and a $30.00 price objective on the stock. The consensus estimate for Tyra Biosciences’ current full-year earnings is ($1.57) per share. HC Wainwright also issued estimates for Tyra Biosciences’ Q4 2025 earnings at ($0.62) EPS, Q1 2026 earnings at ($0.64) EPS, Q2 2026 earnings at ($0.65) EPS, Q3 2026 earnings at ($0.67) EPS and Q4 2026 earnings at ($0.70) EPS.

Tyra Biosciences (NASDAQ:TYRA) last issued its quarterly earnings results on Thursday, May 8th. The company reported ($0.47) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.49) by $0.02.

Separately, Wedbush reissued an “outperform” rating and issued a $30.00 price objective on shares of Tyra Biosciences in a research report on Friday, March 28th. Six equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock presently has an average rating of “Buy” and an average price target of $30.83.

Tyra Biosciences Trading Up 3.1%

Shares of TYRA opened at $9.98 on Wednesday. The stock’s fifty day simple moving average is $9.52 and its 200 day simple moving average is $12.74. Tyra Biosciences has a twelve month low of $6.42 and a twelve month high of $29.60. The firm has a market capitalization of $529.84 million, a P/E ratio of -6.20 and a beta of 1.17.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of the business. Jane Street Group LLC acquired a new position in Tyra Biosciences during the 1st quarter worth $324,000. Woodline Partners LP bought a new stake in shares of Tyra Biosciences in the 1st quarter worth approximately $931,000. Goldman Sachs Group Inc. increased its holdings in Tyra Biosciences by 21.7% in the 1st quarter. Goldman Sachs Group Inc. now owns 78,006 shares of the company’s stock valued at $725,000 after buying an additional 13,896 shares during the period. Polar Asset Management Partners Inc. boosted its holdings in Tyra Biosciences by 27.1% during the first quarter. Polar Asset Management Partners Inc. now owns 141,241 shares of the company’s stock valued at $1,314,000 after purchasing an additional 30,134 shares in the last quarter. Finally, Millennium Management LLC raised its stake in Tyra Biosciences by 28.2% during the first quarter. Millennium Management LLC now owns 404,165 shares of the company’s stock worth $3,759,000 after acquiring an additional 89,024 shares in the last quarter. Institutional investors and hedge funds own 84.14% of the company’s stock.

About Tyra Biosciences

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.